In:
European Journal of Haematology, Wiley, Vol. 98, No. 2 ( 2017-02), p. 106-111
Abstract:
To evaluate the reduction in thrombotic events ( TE ) in patients with essential thrombocythaemia ( ET ) treated with anagrelide versus hydroxyurea + aspirin ( HU + ASA ). Methods A questionnaire was developed using 2008 WHO diagnostic criteria, and thrombotic risk factors were stratified according to Landolfi criteria. Through questionnaire completion, clinicians at Hungarian haematological centres entered data into the Hungarian MPN Registry on patients with myeloproliferative neoplasms. Based on ET registry data, TE s in anagrelide‐treated patients ( n = 139) were compared with HU + ASA ‐treated patients ( n = 141). Results Patients were followed up for (median) 6 yr. TE s were reported in significantly fewer anagrelide‐treated patients versus HU + ASA (15.1% versus 49.6%; P 〈 0.001). Numbers of major arterial and major venous events were similar between the groups, although there were over fivefold more minor arterial and minor venous events in the HU + ASA group ( P 〈 0.001). While median age at diagnosis was older and length of follow‐up shorter in the HU + ASA group ( P 〈 0.05), this did not influence TE incidence; medication and TE before diagnosis only influenced TE incidence. Conclusions Anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous TE s versus HU + ASA over 6 yr. Risk of TE after diagnosis was significantly increased if the patient had TE before diagnosis.
Type of Medium:
Online Resource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2017.98.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2027114-1
